molecule

Emerging infections research to improve global health

The Duke Human Vaccine Institute (DHVI) continues to lead with cutting edge vaccine research against infectious diseases that impact global health. Scientists at the DHVI conduct basic and translational research to develop novel vaccines, therapeutics, and diagnostics for diseases such as HIV-1, tuberculosis, influenza, syphilis, and gonorrhea, and now SARS-CoV-2. Several DHVI basic science discoveries are currently being produced in Good Manufacturing Practice (CGMP) facilities for early phase vaccine trials.

The DHVI has established a place of national and international leadership in the fight against major infectious diseases. We play an integral leadership role in the Global HIV/AIDS Vaccine Enterprise and we are a pioneer in emerging infections and biodefense research.

Join us in leading the fight against major infectious diseases!

OUR MISSION

The Duke Human Vaccine Institute will develop vaccines and therapeutics against diseases of global importance while training the next generation of scientists.

 

OUR VALUES

Collaboration, Excellence and Innovation